These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 29461566)

  • 41. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
    Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Diabetes in Patients with Heart Failure.
    Bowes CD; Lien LF; Butler J
    Curr Cardiol Rep; 2018 Aug; 20(10):97. PubMed ID: 30151728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.
    Rydén L; Shahim B; Mellbin L
    Clin Ther; 2016 Jun; 38(6):1279-1287. PubMed ID: 27107734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
    Berra C; Manfrini R; Regazzoli D; Radaelli MG; Disoteo O; Sommese C; Fiorina P; Ambrosio G; Folli F
    Pharmacol Res; 2020 Oct; 160():105052. PubMed ID: 32650058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
    Basile JN
    Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes.
    Ferraro RA; Nass CM; Dudum R; Blumenthal RS; Sarkar S
    Am J Med; 2019 Sep; 132(9):1027-1031. PubMed ID: 30904510
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.
    Coch RW; Green JB
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):767-72. PubMed ID: 27378397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.
    Iskander C; Cherney DZ; Clemens KK; Dixon SN; Harel Z; Jeyakumar N; McArthur E; Muanda FT; Parikh CR; Paterson JM; Tangri N; Udell JA; Wald R; Garg AX
    CMAJ; 2020 Apr; 192(14):E351-E360. PubMed ID: 32392523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 53. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular outcome trials of the newer anti-diabetic medications.
    Acharya T; Deedwania P
    Prog Cardiovasc Dis; 2019; 62(4):342-348. PubMed ID: 31442511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms.
    Gómez-Peralta F; Abreu C; Rizzo M
    J Diabetes Complications; 2023 Aug; 37(8):108553. PubMed ID: 37385011
    [No Abstract]   [Full Text] [Related]  

  • 60. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.